Monthly Cost Breakdown: Wegovy vs Mounjaro Pricing
Is Wegovy Cheaper Than Mounjaro: Monthly Cost Analysis
When evaluating whether Wegovy is cheaper than Mounjaro on a monthly basis, the answer depends on your specific dose requirements and treatment phase. Wegovy follows a structured 16-week escalation protocol starting at £79.99 for the initial 0.25mg dose, progressing through £94.99 (0.5mg), £99.99 (1mg), and £139.99 (1.7mg) before reaching the maintenance dose of £209.99 monthly. This transparent pricing structure allows patients to budget accurately for their entire treatment journey. Mounjaro uses a different escalation schedule with tirzepatide as its active ingredient, creating distinct monthly cost patterns that may suit different financial preferences.
The question of whether Wegovy is cheaper than Mounjaro becomes more complex when considering bundle pricing and long-term maintenance costs. EverydayMeds offers Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) for £169.99, covering your first two months of treatment. For maintenance dosing, the Consistency 2.4mg bundle provides two months' supply for £419.99, whilst the Ultimate Stability Trio offers three months for £649.99. These bundled options provide convenience and supply security, though individual monthly costs remain the primary consideration for most patients.
Wegovy vs Mounjaro: Pricing Structure and Value Comparison
Understanding whether Wegovy is cheaper than Mounjaro requires examining both medications' complete pricing frameworks throughout treatment phases. Wegovy's semaglutide-based formulation follows NHS-recommended dose escalation protocols, with each monthly cost clearly defined from initiation through maintenance. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access our competitive pricing structure. EverydayMeds operates as a GPhC-registered pharmacy (#9012878), ensuring legitimate prescription-only medicine supply with full regulatory compliance.
The annual cost comparison between Wegovy and Mounjaro reveals important budgeting considerations when determining which treatment offers better value. Wegovy's maintenance dose costs £209.99 monthly, totalling approximately £2,520 annually at the therapeutic 2.4mg strength. This predictable annual expense helps patients plan their healthcare budget effectively, especially when combined with our bundle options that reduce ordering frequency. Both medications require ongoing prescription monitoring and clinical assessment, adding consultation costs that remain consistent regardless of which treatment you choose.
Clinical Evidence Supporting Wegovy vs Mounjaro Cost Effectiveness
When evaluating whether Wegovy is cheaper than Mounjaro, clinical effectiveness data provides essential value context. Wegovy demonstrated significant results in the STEP clinical trial programme, with participants achieving an average of approximately clinically studied weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). These results support the medication's value proposition relative to its monthly costs. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, potentially offering long-term healthcare cost savings.
Mounjaro's tirzepatide mechanism works as a dual GIP and GLP-1 receptor agonist, offering a different therapeutic approach with its own clinical evidence base. However, comparing trial weight loss percentages between medications isn't appropriate due to different study designs, populations, and endpoints. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment provides the best clinical and financial value for your specific circumstances.
How Wegovy Works: Understanding Value Beyond Monthly Costs
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to support weight management goals. This prescription-only medicine works by reducing appetite and promoting feelings of satiety after smaller meals, potentially reducing food cravings through its action on brain appetite centres. The medication is administered once weekly using Novo Nordisk's FlexTouch pen system, providing convenience that justifies its monthly cost structure. Unlike Mounjaro's dual-hormone approach, Wegovy targets the GLP-1 pathway specifically, offering proven efficacy with a well-established safety profile. Understanding this mechanism helps evaluate whether Wegovy is cheaper than Mounjaro when considering therapeutic outcomes alongside financial investment.
Ordering Process: Accessing Wegovy Through EverydayMeds
Obtaining Wegovy involves a streamlined three-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review applications within three working days (express 24-hour service available), ensuring appropriate clinical oversight before prescription approval. Once approved, orders ship via next-day delivery using cold-chain, temperature-controlled packaging to maintain medication integrity. This efficient process applies whether you're comparing costs or ready to begin treatment. The assessment determines your appropriate starting dose and escalation schedule, directly impacting your monthly costs throughout the 16-week titration period.
Storage Requirements and Practical Cost Considerations
Wegovy requires refrigerated storage at 2-8°C before first use, though it remains stable for up to six weeks at room temperature below 30°C once removed from refrigeration. This storage advantage over Mounjaro's 21-day room temperature stability may influence travel and lifestyle costs for frequent travellers. Each FlexTouch pen contains four doses, lasting exactly one month when used weekly as prescribed. The mandatory dose escalation schedule means you cannot skip titration steps, making monthly cost progression predictable and non-negotiable. These practical considerations impact total treatment costs beyond the medication price itself.
Monthly Budgeting Strategy: Long-term Cost Planning for Wegovy vs Mounjaro
Creating a sustainable budget when choosing between Wegovy and Mounjaro requires understanding both immediate escalation costs and long-term maintenance expenses. Wegovy's first four months cost £414.96 total (£79.99 + £94.99 + £99.99 + £139.99), followed by ongoing maintenance at £209.99 monthly. This frontloaded cost structure means lower initial investment compared to some alternatives, making treatment accessible during the crucial early adaptation period. Planning for annual medication expenses helps ensure treatment continuity and optimal outcomes.
Bundle purchasing strategies can optimise your monthly cost management when the question "is Wegovy cheaper than Mounjaro" extends to convenience and supply security. The Ultimate Stability Trio provides three months of maintenance dosing for £649.99, reducing ordering frequency and ensuring consistent medication availability. This approach particularly benefits patients who prefer predictable quarterly healthcare expenses rather than monthly payment cycles, whilst maintaining the same per-dose value as individual purchases.
Making Your Decision: Expert Support for Wegovy vs Mounjaro Choice
Determining whether Wegovy is cheaper than Mounjaro ultimately depends on your individual clinical needs, financial preferences, and treatment response patterns. EverydayMeds provides both options with transparent pricing, clinical assessment, and prescriber support to guide your decision. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine prescription-only medicine with appropriate medical oversight throughout your treatment journey. Use discount code FIRST40 for new customers or DOSE25 for returning patients to access competitive pricing on either medication. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discover which treatment offers the best value for your weight management goals, with expert guidance every step of the way.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
